Options Medical Weight Loss review

The obvious assumption about Options Medical Weight Loss is that the name tells you everything, and it does not. It runs a separate Longevity category with its own program page, its own consultation form and a dedicated NAD⁺ treatment page carrying a flat $199 per month, with glutathione on its own page at $179. For a reader who wants one number rather than a tier ladder, that is useful and rare, and the brand names both its chief medical officer and the pharmacy it works with. The gap is geography: it publishes no list of states its telehealth arm covers, so outside its clinic states you cannot confirm you are eligible before starting.

Options Medical Weight Loss is an established medical weight-loss brand with eleven clinics across Arizona, Florida, Illinois and Ohio plus a telehealth program. Its site is organized by category rather than by drug: Weight Loss (compounded semaglutide and tirzepatide, oral versions of both, phentermine, B12 and lipotropic injections), Hormones (a TRT program and an HRT program, with estradiol, progesterone and testosterone listed as treatments), and Longevity (a Longevity Program with NAD⁺ and glutathione as its named treatments). It says it is LegitScript-certified and is cash-pay with HSA/FSA eligibility stated.

A structured program rather than a medication-only transaction, and the brand is explicit about that framing — it describes GLP-1 medication as one tool inside a broader metabolic-health plan with provider support and accountability, and its telehealth arm runs on video visits from home. On the longevity side, the program page states that a treatment plan is personalized after a comprehensive medical assessment, and the NAD⁺ page lists ongoing monitoring, follow-up and in-clinic continuity of care — the right framing for an injectable. The longevity entry point is a free consultation form that lists only its four clinic states. The clinical bench is named: a providers page lists its nurse practitioners by clinic, with Roscoe Nelson, MD, FACS as chief medical officer, and its FAQ names OptioRx of Columbus, Ohio as the pharmacy it works with. The practical friction is geography. It publishes no state list for telehealth, saying only that you must live in a state where its telehealth service is available, so a reader outside Arizona, Florida, Illinois and Ohio hands over health history before learning whether they qualify. The refund terms are short: its FAQ says a full program refund is available only if you cancel within 24 hours of signing up, and memberships carry a 72-hour refund window.

The NAD⁺ figure is clean and singular: $199 per month, stated on its own NAD⁺ injectable therapy page with a direct purchase button, not quoted after an intake. Glutathione has its own page at $179 per month. Nothing else on the site should be read as an NAD⁺ price. For context on the rest of the menu — and only as context — its telehealth page lists compounded semaglutide injections from $199 a month and compounded tirzepatide from $299 with medication included, oral semaglutide from $239 and oral tirzepatide from $339, while the homepage prices its tirzepatide program from $399 and phentermine from $149. HSA/FSA is accepted and flexible payment options are offered. What the NAD⁺ page does not state is the dose, the vial size or the injection frequency behind the $199, so ask what a month actually contains before comparing it against a competitor's monthly figure. Also ask whether the $199 includes the medical assessment the longevity program describes, or whether that is billed separately.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The brand names OptioRx as its pharmacy, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the longevity line is exactly the part of this market where the marketing runs furthest ahead of the data. Injected NAD⁺ has no controlled human outcome trials — the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly — while the NAD⁺ forms with human trial data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, and what those trials reliably demonstrate is a raised blood NAD⁺ level rather than a clinical benefit. Injectable glutathione has essentially no controlled human outcome data behind the claims attached to it. The compounded GLP-1s on the weight-loss side sit on a different footing: the underlying molecules have large randomized trials, but a compounded preparation of them is not the trialed product. Individual results vary.